Trade Summary

2 months ago, Lynx1 Capital Management LP, serving as 10% owner at Neuphoria Therapeutics Inc. (NEUP), purchased 639,110 shares at $5.14 per share, for a total transaction value of $3,283,108.00. Following this transaction, Lynx1 Capital Management LP now holds 875,328 shares of NEUP.

This purchase represents a 271.00% increase in Lynx1 Capital Management LP's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, October 21, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, October 23, 2025, 2 days after the trade was made.

Neuphoria Therapeutics Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.